Developing Innovative Therapeutics

Our Company

Inflection Biosciences

Jun 4

Inflection Biosciences Announces Pre-Clinical Data for IBL-202 in PTCL Presented at the Inaugural West German Lymphoma Symposium

Dublin, Ireland, June 4 2024 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Inflection Biosciences

Aug 21, 2023

Inflection Biosciences Announces Licensing of PIM kinase Inhibitors to Mysthera Therapeutics

Dublin, Ireland, August 21 2023 Inflection Biosciences (Inflection), a company developing innovative therapeutics for the treatment of...

Inflection Biosciences

Dec 5, 2022

Inflection Biosciences Announces Pre-clinical data for IBL-101 to be Presented at BSI Congress 2022

Dublin, Ireland, December 5, 2022 Inflection Biosciences Ltd, a company developing innovative therapeutics for the treatment of cancer,...